Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Each patient must meet the following criteria to be enrolled in this study.~1. Is a child or an adolescent of 10 to \<18 years old, at Visit 1 (Screening)~2. Has been diagnosed with type 2 diabetes mellitus per American Diabetes Association diagnostic criteria~3. HbA1c of 6.5% to 11.0%, inclusive, in patients not taking insulin/SU, and of 6.5% to 12.0%, inclusive, in patients taking insulin/SU, at Visit 1 (Screening)~4. Has a C-peptide of \>0.6 ng/L at Visit 1 (Screening)~5. Has been treated with diet and exercise alone or in combination with a stable dose of an oral antidiabetic agent (e.g., metformin and/or SU) and/or insulin for their type 2 diabetes for at least 2 months prior to Visit 1 (Screening)~6. Has a fasting plasma glucose concentration \<280 mg/dL (15.5 mmol/L) at Visit 1 (Screening)~Patients who meet any of the following criteria will be excluded from the study.~1. Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the Investigator, including but not limited to the following conditions:~   1. Hepatic disease (defined by aspartate or alanine transaminase \>3.0 times the upper limit of normal (ULN)~  2. Renal disease or serum creatinine \>1.5 mg/dL (132.6 µmol/L) (males) or 1.4 mg/dL (123.8 µmol/L) (females)~  3. Gastrointestinal disease deemed significant by the Investigator~  4. Organ transplantation~  5. Chronic infection (e.g., tuberculosis, human immunodeficiency virus, hepatitis B virus, or hepatitis C virus)~  6. Clinically significant malignant disease (with the exception of basal and squamous cell carcinoma of the skin) within 5 years of Visit 1 (Screening)~2. Has positive antibody titers to glutamic acid decarboxylase (GAD65) or islet cell antigen (ICA512) at Visit 1 (Screening)~3. Has a personal or family history of elevated calcitonin, calcitonin \>100 ng/L, medullary thyroid carcinoma, or multiple endocrine neoplasia-2~4. Has ever used exenatide (exenatide once weekly \[exenatide LAR\], exenatide BID, BYETTA, or any other formulation) or any glucagon-like peptide-1 (GLP-1) receptor agonist (e.g., liraglutide \[Victoza®\])~5. Is pregnant

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- EQW (Type: EXPERIMENTAL): Exenatide once weekly
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).